C/EBPα (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, and specifically in acute myeloid leukaemia (AML) by mutation. Elevated TRIB2 leads to the degradation of C/EBPα p42, leaving p30 intact in AML. Whether this relationship is a cooperative event in AML transformation is not known and the molecular mechanism involved remains elusive. Using mouse genetics, our data reveal that in the complete absence of C/EBPα, TRIB2 was unable to induce AML. Only in the presence of C/EBPα p42 and p30, were TRIB2 and p30 able to cooperate to decrease the latency of disease. We demonstrate that the molecular mechanism involved in the degradation of C/EBPα p42 requires site-specific direct interaction between TRIB2 and C/ EBPα p42 for the K48-specific ubiquitin-dependent proteasomal degradation of C/EBPα p42. This interaction and ubiquitination is dependent on a critical C terminal lysine residue on C/EBPα. We show effective targeting of this pathway pharmacologically using proteasome inhibitors in TRIB2-positive AML cells. Together, our data show that excess p30 cooperated with TRIB2 only in the presence of p42 to accelerate AML, and the direct interaction and degradation of C/EBPα p42 is required for TRIB2-mediated AML.
INTRODUCTION
The C/EBPα (CCAAT/enhancer binding protein α) transcription factor is commonly mutated in acute myeloid leukaemia (AML) and dysregulated in a number of cancers (that is, liver, prostate, lung, squamous cell carcinoma). Mutations in CEBPA occur exclusively in haematological diseases and result in perturbed C/ EBPα protein expression and function. C/EBPα promoter methylation perturbs C/EBPα expression in AML, 1 chronic myeloid leukaemia 2 and head and neck squamous cell carcinoma. 3 In AML, oncogene-mediated dysregulation of C/EBPα mRNA expression and/or protein activity occurs in cytogenetically abnormal subtypes of AML, including AMLs with t(8;21)[AML1-ETO], inv (16) [CBFb-MYH11], t (15;17) [PML-RARA] and t(3;21)(AML-1-MDS-1-Evi-1 fusion protein) translocations, and in cytogenetically normal AMLs with FLT3-ITD mutation, or with elevated TRIB2 expression. 4 C/ EBPα protein is also dysregulated by a number of posttranslational modifications including phosphorylation, sumoylation and ubiquitination. 5 CEBPA is an intronless gene with N terminal transcriptional activation domains and a C terminal basic region leucine zipper (LZ) domain. CEBPA mutations, which occur across the entire coding region, are present in 5% and 10% of childhood and adult AML, respectively. 6 Somatic and inherited mutations in CEBPA cooccur, are often biallelic and are found with higher frequency in cytogenetically normal AML. 7, 8 CEBPA is a favourable prognosis factor in AML, specifically for cases that present with double mutations in CEBPA, typically an N terminal and a C terminal basic region LZ gene mutation. C/EBPα protein exists as two isoforms, a full length C/EBPα p42 isoform classified as a tumour suppressor and an N terminally truncated p30 isoform classified as an oncogene. N terminal mutations typically are frame-shift mutations that lead to a premature stop in translation of p42, while retaining p30 expression. In contrast, C terminal mutations typically are in-frame insertions/deletions in the LZ domain that disrupt DNA binding or dimerization. C/EBPα functions by forming stable homodimers and heterodimers with itself and other C/EBP family members, which act to stabilize their protein expression. 9 TRIB2 is a potent oncogene capable of inducing fully penetrant AML in murine models, and can cooperate with other AML oncogenes to disrupt signalling pathways and transcription factors in AML disease. [10] [11] [12] [13] TRIB2 expression was shown to be elevated in a cohort of AML patients with a mixed myeloid/ lymphoid phenotype and a dysregulated CEBPA gene expression signature. In fact, TRIB2 leads to the degradation of C/EBPα p42 via E3 ligase COP1 binding whilst sparing p30 from degradation, resulting in disturbed granulopoiesis. This modulation of C/EBPα was found to be critical for the induction of AML in vivo.
10,13 E2F1 cooperates with C/EBPα p30 to activate the Trib2 promoter in preleukaemic cells resulting in elevated TRIB2 expression. This was shown to be an important mechanism regulating TRIB2 expression and survival of AML cells. 12 In normal cells, C/EBPα is a key transcription factor in the transition from the pre-granulocyte macrophage to the granulocyte-macrophage progenitor stage of differentiation, and in the transcriptional and epigenetic control of haematopoietic stem cell (HSC) self-renewal. [14] [15] [16] In granulocyte-macrophage progenitor cells, C/EBPα p42 is found bound to the Trib2 promoter 1 and inhibits E2F1-mediated activation of Trib2. At the HSC stage, C/EBPα acts to prime HSCs for differentiation along the myeloid lineage via DNA binding to regulatory regions of genes induced during differentiation. 16 Although conditional Cebpa knockout mice do not develop disease, the loss of Cebpa in adult HSCs leads to an increased number of functional and proliferative HSCs 15, 17 and loss of HSC pool maintenance in serial transplantations. 16 Cebpa expression is required for AML disease initiation by the oncogene MLL-ENL but not for disease maintenance. 18 In contrast, Cebpa is required for the maintenance of Hoxa9/Meis1 AML disease. 19 Loss of Cebpa did not abrogate BCR/ABL-induced leukaemia but it did alter the resultant disease phenotype. 20 Thus, it appears that a certain threshold of C/EBPα expression is important for the development of myeloid leukaemic disease. This is supported by the observation that leukaemia-derived CEBPA mutations are virtually never null mutations. 21, 22 The combination of N and C terminal mutations have distinct features that result in leukaemia development. 23, 24 Murine knockin studies investigating p30 oncogenicity in the absence of C/EBPα p42 showed that p30 induced fully penetrant transplantable AML. 25 p30 is sufficient for haematopoietic commitment to the myeloid lineage, it enables transition from the common myeloid progenitor to the granulocyte-macrophage progenitor stage. However, it does not retain the ability to control proliferation and myeloid progenitors have greatly increased self-renewal capacities. 25 Although TRIB2 disrupts the ratio of C/EBPα p42:p30 and functions to degrade C/EBPα, it is unclear whether the loss of C/EBPα p42 or the expression of C/EBPα p30 is critical for TRIB2-mediated AML disease. Here, we show using mouse genetics that the presence of C/EBPα is paradoxically required for TRIB2-induced AML, and only in the presence of C/EBPα p42, is there a cooperative effect seen with TRIB2 and C/EBPα p30. We dissect the molecular details of the degradative relationship between TRIB2 and C/EBPα p42, and show that the direct interaction between TRIB2 and C/EBPα p42 is required for TRIB2-mediated ubiquitin-dependent proteasomal degradation of C/EBPα p42. We identify lysine 313 of C/EBPα as a site of TRIB2-mediated ubiquitination. We show that we can target TRIB2 AML cells with proteasome inhibition. Together, these data show that C/EBPα presence is required for the initiation of TRIB2-induced AML and subsequent C/EBPα p42/p30 disruption is critical for TRIB2 AML disease.
RESULTS
C/EBPα p42 accelerates AML in the presence of TRIB2 and excess p30 To establish whether C/EBPα is essential for TRIB2-induced AML, we performed a bone marrow (BM) transplant using a previously described conditional Cebpa Figure 1B) . Notably, 14 months after transplantation, CD45.2 + GFP + cells were detected suggesting that the TRIB2-expressing Cebpa Δ/Δ cells are able to properly home to the BM but do not give rise to leukaemia. Therefore, although TRIB2 functions to degrade C/EBPα p42 leading to AML, 10 the complete absence of C/EBPα abrogates TRIB2 oncogenicity. Thus, it appears that a certain threshold of C/EBPα (p42 or p30) expression is necessary for the initiation of TRIB2 AML.
Having established the necessity of C/EBPα expression for TRIB2 AML, we next sought to elucidate whether p42 degradation or p30 accumulation is the key driver of this pathway, and whether p30 can cooperate with TRIB2 to accelerate disease onset. To investigate this, we designed a transplant model which utilized donor cells from an established Cebpa conditional knockout model that only expressed p30 isoform (referred to here as Cebpa Δ/p30 ), or were heterozygous for this allele still expressing p42 on one allele (referred to as Cebpa fl/p30 cells) (see methods and Figure 1b (Figure 1g) ). Taken together, these data show that despite TRIB2 functioning to degrade p42, C/EBPα is essential for the initiation of TRIB2-mediated AML and only in the presence of C/ EBPα p42 is there a cooperative effect seen with p30.
Identification of specific amino acids involved in the TRIB2 and C/EBPα interaction Having shown the requirement for C/EBPα p42 in the initiation of TRIB2-induced AML, we next focused on the interaction between C/EBPα and TRIB2. We first determined using subcellular fractionation and confocal microscopy that the co-localization of TRIB2-C/EBPα was nuclear ( Supplementary Figures 2A and B) . Using GST pull-down experiments, we show that the C terminal LZ domain of C/EBPα is required for the interaction with TRIB2 as a GZ mutant expressing an unrelated LZ could no longer bind TRIB2. However, TRIB2 can still bind a C/EBPα LZ mutant (L12V) that can no longer dimerize, indicating TRIB2 binding to C/EBPα is independent of amino acids involved in C/EBPα dimerization (Supplementary Figures 2C, D and E). To more precisely identify specific regions of interaction with TRIB2, we SPOT-synthesized a peptide array containing a series of 18-amino acid overlapping peptides identical to the C terminus LZ domain of C/EBPα. GST-TRIB2 bound to eight peptides within the C terminus LZ of C/ EBPα (Figure 2a) . To identify the specific amino acids required for the interaction, we used a Specific Alanine Scanning Substitution Array, where consecutive amino acids of the parent peptides were substituted to an alanine. This identified residues R333, R339 and R343 of C/EBPα as potential mediators of interaction with TRIB2 ( Figure 2b ). Using site-directed mutagenesis, we show that mutation of R339A abolished the interaction with GST-TRIB2 in a pull-down assay (Figure 2c ). This was confirmed by co-immunoprecipitation in mammalian cells (Supplementary Figure 2F) indicating that R339 of C/EBPα is required for interaction with TRIB2.
Reciprocally, we used TRIB2 peptide arrays that covered the entire TRIB2 protein to identify specific amino acids in TRIB2 responsible for the interaction with C/EBPα. Recombinant C/EBPα protein bound to peptides that spanned from amino acids 25-318 indicating extensive interaction of C/EBPα with TRIB2 ( Figure 3a) . Specific Alanine Scanning Substitution Array of amino acids in peptide 2 (DHVFRAVLHSHGEELVCK) identified R77, which is homologous to R107 in TRIB1 that exists as a gain-of-function TRIB1 mutation in AML. 26 Specific Alanine Scanning Substitution Array of amino acids in peptide 4 (PEILNTSGSYSGKAADVW) identified a putative GSK3 phosphorylation site (which has the consensus GSK3 phosphorylation site motif S/TXXXS/T). Specific Alanine Scanning Substitution Array of peptide 5 (HPWFSTDFSVSNSGFGAK) identified K322 (Figure 3b ). Three mutants R77A, S227A/S229A/S231A/K233A (4-AA) and K322A were generated (Figure 3c ). Co-immunoprecipitation showed that mutation of the sequence S227A/S229A/S231A/K233A (4-AA) abolished the interaction with C/EBPα completely, and K322A and R77A although reduced could still bind C/EBPα (Figure 3d and Supplementary Figure 2G ).
Ubiquitin-mediated mechanism of TRIB2-induced p42 degradation We next assessed the ability of TRIB2 to induce ubiquitin-specific degradation of C/EBPα. A ubiquitination assay was performed in 293 T cells transfected with C/EBPα, TRIB2 and Ubiquitin (Ub). Increased C/EBPα ubiquitination was observed in TRIB2-expressing cells compared with controls and this was exclusively K48-mediated ubiquitination (proteasome degradation K48-specific polychains as opposed to non-degradative ubiquitination mediated by K63 polychains) as detected by K48-and K63-specific antibodies (Figure 4a ). This was confirmed using ubiquitin mutants, which do not express the K48 ubiquitin polychain (UB/K48R-HA) and the K63 ubiquitin polychain (UB/K63R-HA) in a ubiquitination assay (Figure 4b, compare lanes 7, 8 and 9 ). We show using the R339A C/EBPα-binding mutant that the direct binding between TRIB2 and C/EBPα was required for TRIB2-mediated ubiquitination of C/EBPα compared with the control mutant R343A that retains the TRIB2 interaction (Figure 4c ). Reciprocally, using the TRIB2-binding mutant S227A/S229A/ S231A/K233A (4-AA) revealed a loss in C/EBPα ubiquitination as compared with the mutants R77A and K322A that retain higher C/EBPα-binding affinity or WT TRIB2 (Figure 4d ). Together these data show that the direct binding interaction between TRIB2 and C/EBPα was required for TRIB2-mediated ubiquitination of C/EBPα.
To investigate the site on C/EBPα susceptible to TRIB2-mediated ubiquitination, Ubpred online software analysis of C/EBPα was performed, and it identified a number of lysine residues as . GST pull-down, performed in the presence of MG-132, using GST-TRIB2 followed by western blot analysis for GST (top and bottom panels) and C/EBPα (middle panel).
Deciphering the C/EBPα and TRIB2 relationship C O'Connor et al potential ubiquitination sites with low to high confidence scores. K313 was predicted with medium confidence as a potential ubiquitination site (Figures 5a and b) which has been identified as a recurrent C/EBPα mutation (K313dup) that results in an extra lysine adjacent to K313. This duplication occurs in 10% of C/EBPα-mutated AMLs and identified to have a shorter protein half-life than wild-type C/EBPα as determined by cycloheximide assay. 27 Mutation of K313 to K313R resulted in the loss of TRIB2-induced C/EBPα ubiquitination as compared with WT C/EBPα (Figure 5c) . As a control, we show that this mutation retains functional C/EBPα transcriptional activity as both WT and mutant C/EBPα stimulated the G-CSFR luciferase reporter construct, a known C/EBPα target gene (Figure 5d ). These data show that K313 serves as the site of ubiquitin conjugation on C/EBPα in the presence of TRIB2 and mutation of K313 abrogates TRIB2-mediated ubiquitin-dependent proteasomal degradation of C/EBPα. This site is also present in p30 yet we do not observe TRIB2-mediated p30 ubiquitination (Figure 5e ), suggesting that perhaps the N terminus of C/EBPα p42 functions in the degradative complex.
Proteasome inhibition selectively targets AML with high TRIB2 expression Our data suggest that inhibition of the proteasome would effectively inhibit the function of TRIB2 by abrogating C/EBPα protein degradation and would be an effective pharmacological targeting strategy in TRIB2-positive AMLs. To test this, U937 cells (express detectable levels of endogenous TRIB2 and C/EBPα) transduced with retroviral MigR1-GFP control and MigR1-TRIB2-GFP were treated with 10 nM bortezomib (a reversible inhibitor of the proteasome chymotryptic activity resulting in the accumulation of K48 ubiquitin-linked proteins). An increase in cytotoxicity in the TRIB2-overexpressing cells compared with MigR1 control transduced cells was observed and cells expressing TRIB2-VPM that cannot degrade C/EBPα behaved similarly to control cells (Figure 6a, panels 1 and 2) . Overexpression of MigR1-C/EBPα was able to rescue bortezomib-induced cell death in U937 cells (Figure 6a, panels 3) . In C/EBPα-negative leukaemia cells, K562 and Kasumi 1 bortezomib toxicity was not increased following TRIB2 overexpression supporting the specificity of bortezomib on the TRIB2-C/EBPα axis (Figure 6a , panels 4 and 5). Second generation irreversible proteasome inhibitors 28,29 also showed selective killing of high TRIB2 (lentiviral Phr-GFP)-expressing AML cells as assessed by cell viability (Figure 6b ). Bortezomib treatment rescued the degradation of C/EBPα p42 seen with TRIB2 overexpression in U937 cells (Figure 6c ). In fact, p30 expression remains upon TRIB2 overexpression, confirming our ubiquitination data in Figure 5 . We next established a human AML orthotopic xenograft model in which U937 cells were propagated in NSG xenografts and mice were either treated with bortezomib in vivo ( Figure 6d and described in methods), or TRIB2 was knocked down using shRNA lentivirus (Figure 6e 12 ). In vivo bortezomib treatment significantly impaired the engraftment of U937 cells as determined by lower % of engrafting GFP + cells positive for human antibody CD45 expression (Figure 6f ). In addition, engraftment of U937 cells expressing shTRIB2 lentivirus in NSG xenografts showed that in comparison with control (shctrl), knockdown of TRIB2 impaired the progression of U937 orthotopic xenografts (Figure 6g ). Together our data show that TRIB2-expressing AML cells can be pharmacologically targeted with proteasome inhibition due, in part, to inhibition of the TRIB2 proteolytic function on C/EBPα.
DISCUSSION
Although C/EBPα dysfunction is a common occurrence in different cancers, details on the mechanisms involved in bringing about the loss of C/EBPα protein expression in Cebpa wild-type and mutated AML are yet to be fully elucidated. In this study, we identify the molecular mechanism involved in the dysregulation of C/EBPα expression via TRIB2 in AML. We and others 10, 13, 30 have previously demonstrated that TRIB2 overexpression induces AML and that it degrades C/EBPα p42. Here, we provide novel insights on this process and show that the presence of C/EBPα p42 is required not only to initiate TRIB2 AML, but also for TRIB2 to cooperate with C/EBPα (p42 loss and increased p30) in driving AML disease. Our data support the emerging notion that C/EBPα functions in the initial transformation, as supported by the data showing that C/EBPα regulated a transcriptional programme essential for initiation yet dispensable for the maintenance of MLL-ENL disease. 18 Our data clearly show loss of C/EBPα p42 via TRIB2-induced ubiquitin-mediated degradation and excess p30 expression cooperates to accelerate AML.
Using BM transduction and transplantation approaches, we show that C/EBPα p42 isoform expression from one Cebpa allele is necessary and sufficient for TRIB2 to cooperate with p30 isoform in AML. The addition of TRIB2 does not further accelerate AML induced by excess p30 itself, but does accelerate AML when p42 is present. This suggests that p30 is necessary for TRIB2-mediated AML induction. The possibility remains that TRIB2 may convert p42 to p30 to form additional p30 protein but we do not have any evidence for this here. Under normal physiological conditions, the protein levels of C/EBPα p42 are greater than p30 protein levels, and when this balance changes toward more p30 levels, it is considered 'leukaemic', as observed in leukaemic cell lines and AML patients. 22 We showed that K313 in the C terminus of C/EBPα p42 was critical for TRIB2-mediated ubiquitination and proteasomal degradation. This lysine residue is a common mutation in AML patients (~10% of all C/EBPα mutations) which results in the duplication of the single lysine to KK leading to Deciphering the C/EBPα and TRIB2 relationship C O'Connor et al reduced protein stability. 27 Using mouse genetics, it was shown that this duplication of K313 to K313KK (K313dup) resulted in an increased proliferation of long-term HSCs leading to an expansion of premaligant HSCs not seen with the N terminal mutations. 23 Our data show that the absence of this lysine by mutation to an arginine (K313R) abrogates the susceptibility of C/EBPα to degradation whilst retaining its DNA-binding and transcriptional activation function. This suggests that TRIB2 degrades C/EBPα p42 via ubiquitination of K313 and duplication of this residue as occurs in AML patients samples would lead to an increase in C/EBPα p42 degradation in the presence of TRIB2. Patients with K313dup had TCR rearrangements and CD7 expression, 27 lymphoid features associated with unfavourable outcome and which we have previously linked with TRIB2 and C/EBPα perturbation. 31 Previous investigation of the combination of a C terminal mutation (K313 duplication) with C/EBPα p30 expression revealed cooperation and provides a possible explanation for the high prevalence of one N terminal mutation and one C terminal mutation in~90% of biallelic C/EBPα-mutant AMLs. 23 We propose that the K313dup mutation in patients contributes to leukaemic transformation by increasing the susceptibility of C/EBPα to ubiquitination resulting in increased degradation of C/EBPα p42. A thorough investigation of TRIB2 function in K313 mutant patient cells would further validate this.
C/EBPα p42 R339 and K313 amino acids are both present in p30 yet TRIB2 does not degrade p30. One explanation may be that the protein complexes containing TRIB2 and C/EBPα p42 or TRIB2 and p30 are different. Our previous work showed that TRIB2 binds with COP1 E3 ligase and this interaction is necessary for C/EBPα p42 degradation. 13 Although our peptide mapping clearly shows specific sites in both TRIB2 and C/EBPα responsible for the direct interaction, in the absence of crystal structure information, we cannot predict further based on our data the reason why p30 is not targeted by TRIB2 for degradation. Our data do not discount a role for p30 in TRIB2-mediated AML; p30 presence may, for example, activate a unique set of genes, inhibit other C/EBPs or bind to a unique set of proteins distinct from C/EBPα p42 as previously reported. 32, 33 Indeed, U937 cells express endogenous C/EBPα but are less sensitive to bortezomibinduced killing compared with TRIB2-overexpressing cells. This suggests that TRIB2 must be affecting something in addition to C/EBPα p42 degradation to provide synergy in AML. Our data support further investigations into the proteomic profiling of AML, with a focus on the involvement of C/EBPα ubiquitination and the need for an in-depth understanding of the C/EBPα ubiquitin regulatory pathway in normal versus leukaemic (CEBPA WT and mutant) settings.
Whilst TRIB2 itself is an oncogene capable of driving AML, the molecular interaction identified here between TRIB2 and C/EBPα leading to dysregulated C/EBPα may have implications in other models of AML and indeed other cancers. It is clear that the loss of C/EBPα function is a common occurrence in a number of different cancer types. What is not clear at this point is the extent of the involvement of TRIB2 function across different haematological malignancies and other cancers. To date, cooperation between TRIB proteins and other oncogenes in AML has been demonstrated, most often with Hoxa9 and Meis1, suggesting that TRIB2 protein function downstream of commonly occurring oncogenic events may impact on C/EBPα. 34, 35 TRIB2 is found elevated in lung cancer and associated with the E3 ligase TRIM21. 30 In liver cancer cells, TRIB2 associated with other E3 ligases including β-TrCP, COP1 and Smurf1. 36 Thus, there is a strong link between TRIB2 and the ubiquitin-proteasome system in cancer.
As shown here, high TRIB2-expressing cells are sensitive to bortezomib-induced cellular toxicity. However, inhibition of the proteasome also targets other proteins, E3 ligases and their substrates. We currently have limited knowledge of TRIB2 degradation substrates in general, and indeed knowledge of TRIB2 as a substrate itself of the ubiquitin-proteasome system in cancer. This study highlights the important molecular interplay between TRIB2 and C/EBPα in driving AML, and provides a framework for further investigations into targeting the ubiquitin-proteasome system as an emerging cancer therapy. 
MATERIALS AND METHODS

Murine BM transduction and transplantation
-TRIB2 (n = 8). Mice were monitored for 14 months and killed when they developed physical signs of disease (behavioural changes, laboured breathing, hunched posture) or high white blood cell counts. For NOD-SCID IL2Rγnull (NSG) mice Xenograft transplantation, 1 × 10 6 U937 cells transduced with shTRIB2-GFP (n = 5) or shCtrl-GFP (N = 8) were transplanted into non-irradiated NSG mice via tail vein injection. To assess bortezomib in vivo efficacy, GFP ctrl transduced U937 cells were injected, and 5 days post injection, mice were randomized and treated with either bortezomib (0.5 mg/kg, n = 3) or phosphate-buffered saline (intraperitoneal administration, n = 3) at days 5, 7 and 11 post transplant, which was well tolerated. Mice were killed on day 16. Animals were maintained at the University of Copenhagen and the University of Glasgow, housed in accordance with their respective institutional guidelines. All work was carried out under the approval of the Danish Ethical Committee and the Home Office of the United Kingdom.
Flow cytometry
Cell suspensions were stained on ice in fluorescence-activated cell sorting buffer (phosphate-buffered saline pH 7.0, 10 mM Hepes, 0.02% sodium azide, 0.2% bovine serum albumin). Analytical flow cytometry was performed on a FACS Canto (Becton Dickinson), sorting was performed on a FACS Aria II (Becton Dickinson, Oxford, UK) and data were analysed using FlowJo software (Treestar, Version 10, Ashland, OR, USA). Dead cells were excluded using 4 0 ,6-diamidino-2-phenylindole and doublets excluded based on FSC-H and FSC-A. For apoptosis assays, Annexin V-PE (BD Biosciences 556422) or Annexin V-APC (BD Biosciences 550475, Oxford, UK) was used.
Details of vectors, antibodies, cell culture/transfections and real-time PCR provided in Supplementary Information.
Ubiquitination assay, co-immunoprecipitation and western blotting 293 T cells transfected with described vectors were treated with 10 μM MG-132 5 h prior to lysis where indicated. For ubiquitination assay, cells were lysed in 1% SDS, sonicated and supernatants precleared with Protein G Sepharose 4 fast flow beads (GE Healthcare, Amersham, UK), then incubated with C/EBPα antibody overnight. For co-immunoprecipitation, cells were lysed in Tris buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 5% glycerol, with protease and phosphatase inhibitors) and precleared lysates were incubated with C/EBPα antibody overnight. Whole cell proteins were isolated by RIPA lysis buffer (50 mM Tris, pH 8.0, containing 0.5% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 20 mM N-Ethylmaleimide with protease and phosphatase inhibitors) or by direct lysis (2 × SDS sample buffer). Details of antibodies provided in Supplementary Information. For GST-IP, 3 mg of indicated cell lysate was added to 50 μl of GSH slurry with pulldown performed using 25 ug of GST or GST-TRIB2 (details of GST protein production are provided in Supplementary Information). Densitometric analysis of bands was carried out with ImageJ Software. n ⩾ 3 for all co-immunoprecipitation and ubiquitination assays.
Spot synthesis of peptides and overlay analysis
Peptide arrays were performed as previously described 37, 38 (n = 2) and details are provided in Supplementary Information. Briefly, peptide arrays encompassing the C terminus of C/EBPα and the entire TRIB2 protein were generated and incubated with GST-TRIB2 or purified C-teminal C/EBPα (Genway, San Diego, CA, USA). Arrays were incubated with secondary antibodies and bound protein detected using ECL or the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).
Statistical analysis
Statisitcal analysis and graphing was performed on GraphPad Prism (version 5.03). When comparing two groups, an unpaired, two-tailed Student's t test was used. The Log-rank test was used to compare groups on a survival curves. Statistical significance was attained when the P value ⩽ 0.05 and was indicated in the related figure legends and graphs.
